By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – French biopharmaceutical firm Transgene today announced Beckman Coulter will develop a companion diagnostic for Transgene to measure levels of activated Natural Killer (aKN) cells so that patients can be selected for treatment with an immunotherapy candidate for non-small cell lung cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.